MedTrace Logo

Cellular Reprogramming-Enhanced Skin Grafting for Diabetic Foot Ulcers

NCT02070835 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2026-02-18

No results posted yet for this study

Summary

Diabetic foot ulcer is one of the refractory wounds and always poses many challenges in clinical practice. This study was conducted to have a prospective, randomised, controlled study compare the safety and efficacy of the autologous skin cell with skin graft (experiment group) with split-thickness skin graft (STSG, control group) alone on treating diabetic foot ulcers.

Conditions

  • Diabetic Foot Ulcer

Interventions

DEVICE

autologous skin cell

autologous skin cell and skin graft

PROCEDURE

skin graft

split-thickness skin graft

Sponsors & Collaborators

  • Hu Zhicheng

    lead OTHER

Principal Investigators

  • Jiayuan Zhu, PI · Department of Burns, The First Affiliated Hospital, Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2023-12-30
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02070835 on ClinicalTrials.gov